Dysphagia
is the inability to swallow safely, and about 29% to 55% of stroke
patients experience this condition. It can also be a result of many
other
diseases.
In
this new agreement, NHSc will make an upfront payment to acquire
Phagenesis, and will follow with milestone-based funding throughout the
clinical
evaluation of Phagenyx. Phagenyx is a medical device aimed at treating
the cause of dysphagia, rather than only the symptoms. The device helps
to restore the neurological control of swallowing.
Phagenyx
uses a base station and catheter to deliver stimulation to the pharynx.
Treatment occurs for 10 minutes a day over three days. Stimulation
levels
are personalized and can be controlled via the base station.Click here to learn more.
No comments:
Post a Comment